AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. The post AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line…

Read More

New Campaign Wants AI Applications To Look Beyond Speed

Healthcare has plenty of tedious administrative work which could benefit from AI’s efficiency – but what if simply speeding up an already broken system isn’t the answer? Healthcare leaders push for a re-built, AI-native system in Anterior’s recent Beyond Faster Horses campaign. The post New Campaign Wants AI Applications To Look Beyond Speed appeared first…

Read More

The page says $249 a month. The math says $747.

By JOHN SAMARAS Noom Med prices a GLP-1 plan at $249 a month. The last two words on the line matter. “$129 To get started. $249/mo after the first 4-week supply (billed quarterly).” That’s Noom’s pricing page on November 3, 2026. If a quarterly charge covers three months at $249, it comes to $747. In…

Read More

Dr. Oz at Medicare: Why America’s 53 Million Family Caregivers May Finally Get Their Due

While many view Dr. Mehmet Oz’s nomination to lead the Centers for Medicare and Medicaid Services (CMS) with skepticism, there’s a compelling case that his unconventional background could catalyze long-overdue support for family caregivers. The post Dr. Oz at Medicare: Why America’s 53 Million Family Caregivers May Finally Get Their Due appeared first on MedCity…

Read More